Melemadathil 2013.

Methods	Study design: parallel, open‐label RCT Duration of study: not reported Follow‐up: 1 year ADPKD assessment: magnetic nuclear imaging
Participants	Country: India Setting: not reported ADPKD type 1 after genetic typing; aged 18 to 60 years; GFR > 40 mL/min/1.73 m2; proteinuria < 0.5 g/24 h; informed consent Number: treatment group (40); control group (20) Mean age ± SD (years): not reported Sex (M/F): not reported Exclusion criteria: proteinuria > 0.5 g/24 h or abnormal urinalysis; DM; malignancy; psychiatric disorder; hepatitis B, C; HIV; pregnancy and lactation; increased liver enzymes; dyslipidaemia; granulocytopenia or thrombocytopenia; co‐medication with strong inhibitor of CYP3A4; hypersensitivity
Interventions	Treatment group Sirolimus: 2 mg/d Control group Standard treatment Duration of intervention 6 months extended to 1 year
Outcomes	Kidney volume Cyst volume Parenchymal volume Proteinuria and other laboratory data Adverse events
Notes	Abstract‐only publication Funding source: not reported
Risk of bias
Bias	Authors' judgement	Support for judgement
Random sequence generation (selection bias)	Unclear risk	Randomised 2:1. Sequence generation not defined
Allocation concealment (selection bias)	Unclear risk	Insufficient information to permit judgement
Blinding of participants and personnel (performance bias) All outcomes	High risk	Open‐label study
Blinding of outcome assessment (detection bias) All outcomes	High risk	Open‐label study
Incomplete outcome data (attrition bias) All outcomes	High risk	6/40 (15%) patients in the mTOR group dropped or were lost to follow up. Unclear whether the study was analysed on ITT or PP basis
Selective reporting (reporting bias)	Unclear risk	Insufficient information to permit judgement
Other bias	Unclear risk	Insufficient information to permit judgement